Avastin fails to win FDA panel support

12/5/2007 | Wall Street Journal (free content), The · NYTimes.com

An FDA advisory panel voted 5-4 Wednesday against approving Genentech's cancer drug Avastin as a first-line treatment for patients with recurrent or metastatic breast cancer. A National Cancer Institute study showed no significant difference in overall survival for patients who took Avastin with Taxol compared to those taking Taxol alone.

View Full Article in:

Wall Street Journal (free content), The · NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC